MX9203011A - Procedimiento para preparar una solucion acuosa de fragmento de factor de von willebrand alterado con cisteina y solucion terapeutica fundida mediante el mismo - Google Patents
Procedimiento para preparar una solucion acuosa de fragmento de factor de von willebrand alterado con cisteina y solucion terapeutica fundida mediante el mismoInfo
- Publication number
- MX9203011A MX9203011A MX9203011A MX9203011A MX9203011A MX 9203011 A MX9203011 A MX 9203011A MX 9203011 A MX9203011 A MX 9203011A MX 9203011 A MX9203011 A MX 9203011A MX 9203011 A MX9203011 A MX 9203011A
- Authority
- MX
- Mexico
- Prior art keywords
- fragment
- solution
- cysteine
- preparing
- von willebrand
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Una solución acuosa de fragmento de factor de Von Willebrand alterado con cisteína, que está substacialmente libre y agregado y que es suceptible de utilizarse terapéuticamente para tratar trombosis y un procedimiento para tratar dicha solución, que comprende: (A) proveer una solución acuosa de fragmento y desnaturalizante; (B) purificar la solución o fragmento y desnaturalizante bajo condiciones que promueven la conversión de las formas de agregado del fragmento a las formas dimérica y/o monomérica del mismo, para proveer el fragmento purificado.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71794291A | 1991-06-20 | 1991-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9203011A true MX9203011A (es) | 1993-08-01 |
Family
ID=24884150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9203011A MX9203011A (es) | 1991-06-20 | 1992-06-19 | Procedimiento para preparar una solucion acuosa de fragmento de factor de von willebrand alterado con cisteina y solucion terapeutica fundida mediante el mismo |
Country Status (9)
Country | Link |
---|---|
US (1) | US5539086A (es) |
EP (1) | EP0590048B1 (es) |
AT (1) | ATE283864T1 (es) |
AU (1) | AU2253392A (es) |
CA (1) | CA2110585C (es) |
DE (1) | DE69233451T2 (es) |
ES (1) | ES2233924T3 (es) |
MX (1) | MX9203011A (es) |
WO (1) | WO1993000107A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5316757A (en) * | 1984-10-18 | 1994-05-31 | Board Of Regents, The University Of Texas System | Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups |
US5849536A (en) * | 1990-03-02 | 1998-12-15 | Bio-Technology General Corp. | Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same |
US5847086A (en) * | 1991-06-20 | 1998-12-08 | Centeon L.L.C. | Therapeutic fragments of von Willebrand factor |
US6821943B2 (en) | 2001-03-13 | 2004-11-23 | S. C. Johnson & Son, Inc. | Hard surface antimicrobial cleaner with residual antimicrobial effect comprising an organosilane |
WO2003097669A2 (en) * | 2002-05-17 | 2003-11-27 | Københavns Universitet | Method for purifying denatured proteins having a desired disulfide bond configuration |
US7566701B2 (en) * | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
US20070066551A1 (en) * | 2004-09-07 | 2007-03-22 | Keefe Anthony D | Aptamer medicinal chemistry |
KR20070101227A (ko) | 2004-09-07 | 2007-10-16 | 아케믹스 코포레이션 | 폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도 |
US20090203766A1 (en) * | 2007-06-01 | 2009-08-13 | Archemix Corp. | vWF aptamer formulations and methods for use |
US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
TWI600437B (zh) * | 2007-12-28 | 2017-10-01 | 巴克斯歐塔公司 | 重組vwf調配物 |
AU2014202595A1 (en) * | 2007-12-28 | 2014-06-05 | Baxalta GmbH | Recombinant VWF Formulations |
JP5781931B2 (ja) | 2008-10-21 | 2015-09-24 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 凍結乾燥した組換え型vwf製剤 |
RU2579977C2 (ru) * | 2009-11-13 | 2016-04-10 | Грифольс Терапьютикс Инк. | СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ |
AU2016204172A1 (en) * | 2016-06-20 | 2018-01-18 | The University Of Sydney | Allosteric regulation of haemostatic activity |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8403473D0 (en) * | 1984-02-09 | 1984-03-14 | Special Trustees For St Thomas | Purification of factor viii |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
DE3751179T2 (de) * | 1986-05-30 | 1995-07-27 | Scripps Research Inst | Peptide, die die Bindung des Von-Willebrand-Faktors inhibieren. |
US5043429B1 (en) * | 1987-05-01 | 1997-10-14 | Scripps Research Inst | Protein fragments containing factor VIII binding domain of von willebrand factor |
US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
US5104651A (en) * | 1988-12-16 | 1992-04-14 | Amgen Inc. | Stabilized hydrophobic protein formulations of g-csf |
US5530100A (en) * | 1990-05-07 | 1996-06-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Methods for purification of recombinantly produced proteins |
-
1992
- 1992-06-19 EP EP92914056A patent/EP0590048B1/en not_active Expired - Lifetime
- 1992-06-19 DE DE69233451T patent/DE69233451T2/de not_active Expired - Lifetime
- 1992-06-19 MX MX9203011A patent/MX9203011A/es active IP Right Grant
- 1992-06-19 WO PCT/US1992/005215 patent/WO1993000107A1/en active IP Right Grant
- 1992-06-19 AU AU22533/92A patent/AU2253392A/en not_active Abandoned
- 1992-06-19 ES ES92914056T patent/ES2233924T3/es not_active Expired - Lifetime
- 1992-06-19 CA CA002110585A patent/CA2110585C/en not_active Expired - Lifetime
- 1992-06-19 AT AT92914056T patent/ATE283864T1/de active
-
1994
- 1994-02-18 US US08/198,849 patent/US5539086A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU2253392A (en) | 1993-01-25 |
WO1993000107A1 (en) | 1993-01-07 |
DE69233451T2 (de) | 2006-01-12 |
ATE283864T1 (de) | 2004-12-15 |
EP0590048B1 (en) | 2004-12-01 |
EP0590048A1 (en) | 1994-04-06 |
EP0590048A4 (en) | 1994-06-08 |
CA2110585C (en) | 2004-10-12 |
DE69233451D1 (de) | 2005-01-05 |
ES2233924T3 (es) | 2005-06-16 |
CA2110585A1 (en) | 1993-01-07 |
US5539086A (en) | 1996-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9203011A (es) | Procedimiento para preparar una solucion acuosa de fragmento de factor de von willebrand alterado con cisteina y solucion terapeutica fundida mediante el mismo | |
YU159291A (sh) | Analozi azota sa kondenzovanim prstenom koji sadrže nearomatske heterocikle | |
MY103892A (en) | Interleukin-2 of high purity production and use | |
DK450785D0 (da) | Fremgangsmaade til fremstilling af et koncentrat af antihaemofilisk faktor med hoej renhed | |
SE9402595D0 (sv) | Förfarande för kristallisation av iopamidol | |
ES8504255A1 (es) | Procedimiento para la produccion de una hormona de crecimiento de porcino. | |
FI885807A (fi) | Puhdistetun, biologisesti aktiivisen, bakteerien avulla tuotetun rekombinanttisen ihmis- CSF-1:n tuottaminen | |
ATE63750T1 (de) | Peptid, dessen herstellung und benutzung. | |
MX9302279A (es) | Metodo para la produccion del factor viii presenteen el plasma, altamente purificado. | |
ES8601236A1 (es) | Un procedimiento para la preparacion de derivados peptidicos | |
FR2689503B1 (fr) | Procede d'epuration d'un hydrofluoroalcane. | |
DE69637464D1 (de) | Therapeutische fragmente des "von willebrand" faktors | |
FI953507A (fi) | Katalyyttejä, joissa aktiiviset komponentit ovat hyvin hienojakoisina | |
FR2610633B1 (fr) | Procede d'obtention d'un concentre d'a 1-antitrypsine a partir de plasma humain et son utilisation a titre de medicament | |
IT1254635B (it) | Processo per la separazione degli stereoisomeri dell'acido folinico | |
DE69129693T2 (de) | Verwendung von nickel und bromide ionen für die behandlung von psoriasis | |
DE68903907D1 (de) | Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen. | |
FR2388824A1 (fr) | 3,1-s-a2-glycoproteine riche en leucine, son procede de preparation et son utilisation | |
DE3680770D1 (de) | Ausgangsprodukte zur herstellung von 9-beta-chlorprostaglandinen. | |
BG90414A (bg) | 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им | |
SE7906137L (sv) | Rening av faktor viii | |
JPS529700A (en) | Manufacturing method of high purity caustic soda solution | |
ATE24834T1 (de) | Verwendung von beta-(1-adamantyl)-alpha, alphadimethylethylamin zur herstellung eines arzneimittels zur behandlung von otitis externa bei hunden. | |
MC1627A1 (fr) | Procede de production d'un interferon immun | |
ATE22009T1 (de) | Verwendung von alpha, alphadialkyladamantylethylaminen zur behandlung von masernvirus. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights | ||
HC | Change of company name or juridical status | ||
HC | Change of company name or juridical status | ||
FG | Grant or registration |